Fu Xi-Yong reports option and share holdings in NovaBridge Biosciences (NBP)

Rhea-AI Filing Summary

NovaBridge Biosciences director and officer Fu Xi-Yong has filed an initial ownership report detailing equity interests in the company. The filing lists 2025 employee share options tied to 1,245,000 ordinary shares, with an exercise price of 1.07 per ADS and an expiration date of 2034-10-30. These options were granted on November 1, 2024 and vest in four equal annual installments starting on the first anniversary of the grant date.

The report also shows restricted share units linked to 1,245,000 underlying ordinary shares, each RSU representing a contingent right to receive one ADS that vests in four installments if the ADS achieves specified price targets. In addition, Fu Xi-Yong directly holds 59,823 ordinary shares, represented by 26,010 ADSs. Each 10 ADSs represent 23 ordinary shares of NovaBridge Biosciences.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fu Xi-Yong

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	59,823(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2025 Employee Share Option (right to buy)	(4)	10/30/2034	Ordinary Shares(1)	1,245,000(3)	$1.07(3)	D
Restricted Share Units	(5)	(5)	Ordinary Shares(1)	1,245,000(3)	(5)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 26,010 ADSs.

3. Number of underlying securities and exercise price expressed in terms of ADSs.

4. The option was granted on November 1, 2024. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of the grant date.

5. Each restricted share unit ("RSU") represents a contingent right to receive one ADS. The RSUs vest, if at all, in four separate installments upon the Issuer's ADS's achieving certain specified prices per share. The RSUs have no expiration date.

Remarks:

Chief Executive Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Fu Xi-Yong’s Form 3 for NovaBridge Biosciences (NBP) report?

The Form 3 reports Fu Xi-Yong’s initial ownership in NovaBridge Biosciences, including options over 1,245,000 ordinary shares, restricted share units tied to 1,245,000 ordinary shares, and 59,823 directly held ordinary shares represented by 26,010 ADSs.

How many NovaBridge Biosciences ordinary shares does Fu Xi-Yong hold directly?

Fu Xi-Yong directly holds 59,823 ordinary shares of NovaBridge Biosciences. According to the disclosure, these ordinary shares are represented by 26,010 American Depositary Shares (ADSs), using the company’s stated ratio of 10 ADSs to 23 ordinary shares.

What equity awards does Fu Xi-Yong have in NovaBridge Biosciences (NBP)?

Fu Xi-Yong holds 2025 employee share options tied to 1,245,000 ordinary shares and restricted share units linked to 1,245,000 ordinary shares. The options and RSUs provide potential future ADSs, subject to vesting schedules and specified share price conditions.

What are the key terms of Fu Xi-Yong’s 2025 employee share options at NovaBridge Biosciences?

The 2025 employee share options have an exercise price of 1.07 per ADS, are linked to 1,245,000 underlying ordinary shares, and expire on October 30, 2034. They were granted on November 1, 2024 and vest in four equal annual installments beginning one year later.

How do the NovaBridge Biosciences ADSs relate to ordinary shares in Fu Xi-Yong’s Form 3?

Each 10 NovaBridge Biosciences ADSs represent 23 ordinary shares. The filing notes that Fu Xi-Yong’s reported ordinary share holdings are represented by 26,010 ADSs, and that option and RSU underlying share counts and exercise price are expressed in ADS terms.

How do Fu Xi-Yong’s restricted share units in NovaBridge Biosciences vest?

Each restricted share unit represents a contingent right to receive one ADS. The RSUs vest, if at all, in four separate installments when NovaBridge Biosciences’ ADS achieves certain specified prices per share, and the RSUs do not have an expiration date.